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The changing management of primary mycotic
aortic aneurysms
Nadia Vallejo, MD, Natasha Emma Picardo, MRCS, Patricia Bourke, BSc, Colin Bicknell, MD, FRCS,
Nicholas J.W. Cheshire, MD, FRCS, Michael P. Jenkins, MS, FRCS, John Wolfe, MS, FRCS, and
Richard G.J. Gibbs, MD, FRCS, London, United Kingdom
Objective: The objective of this study is to examine contemporary management of primary mycotic aortic aneurysms in a
single center. We have previously reported the management of mycotic aortic aneurysms in 15 patients between 1991 and
2001, and we hypothesized that management would change in the light of the evolution of endovascular aortic repair.
Methods: A review of a prospectively collected database (2002-2009) of all patients presenting with mycotic aneurysms.
Results:A total of 19 aneurysms were identified in 17 patients (12 men, 5 women) with a median age of 66.2 years (range,
49-82 years). All were symptomatic, and nine had contained rupture. There were five infrarenal, two juxtarenal, three
Crawford type III, four type IV thoracoabdominal aortic aneurysms, and five descending thoracic aneurysms in the series.
All thoracic aneurysms were excluded by thoracic endovascular aneurysm repair. Two patients underwent visceral hybrid
endografting for type III thoracic aortic aneurysm; the third was treated with open repair. Four patients underwent open
type IV repair. Two of the infrarenal aneurysms were treated with bifurcated endovascular aneurysm repair, and the other
three and both juxtarenals with open repair with in situ reconstruction. There were three early (17.6%) and three late
deaths (17.6%). The median follow-up was 30.5 months (range, 1-102 months).
Conclusions: The results of the latest series show that open surgery is still required in many cases. The introduction of
endovascular techniques in the exclusion of mycotic aneurysms can be accomplished with acceptable results, and
endovascular treatment has increased the therapeutic options for a difficult condition. (J Vasc Surg 2011;54:334-40.)
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iPrimary mycotic aneurysms of the aorta (MAA) are a
rare condition, constituting 0.65% to 1.3% of all aortic
aneurysms.1,2 The natural disease course is usually fatal,
with a high risk of expansion and rupture.3 The treatment
of choice has traditionally been surgical resection, debride-
ment of infected periaortic tissues, and reconstruction of
the aortic flow either anatomically or extra-anatomically
together with long-term antibiotic treatment.4 However,
surgical management is associated with a highmortality (up
to 40%)1,5,6 due to the severe medical comorbidities, the
magnitude of the surgery, and patient instability because of
systemic sepsis or rupture.
Treatment of aortic aneurysms has evolved over the
past two decades, and endovascular aneurysm repair has
become the treatment of choice in many settings. It is a less
invasive treatment modality than open repair and offers
obvious advantages in terms of reduced perioperative mor-
bidity andmortality in high-risk patients withMAAs. In the
scenario of acute rupture of MAAs, endovascular exclusion
can represent a bridging procedure to a later surgical ap-
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334roach when stability has been obtained as well as a defin-
tive treatment in its own right.
We have observed a change of practice predicated on
he endovascular approach in the treatment ofMAAs in our
enter. We have previously reported our management of
bdominal and thoracoabdominal (TAAA) mycotic aortic
neurysms from 1991 to 2001,7 when 15 patients were
reated with open surgery with anatomic or extra-anatomic
rosthetic repair. Here we report the management of 19
AAs between 2002 and 2009.
ETHODS
A review of a prospectively collected computerized
atabase of all patients with primarily infected aortic aneu-
ysms was conducted. From January 2002 to December
009, 19 MAAs were identified in 17 patients.
Mycotic aneurysms were defined by the presence of two
r more of the following features: sepsis (fever, leukocyto-
is, and pain), positive blood culture, and positive culture
rom the aneurysmal wall or characteristic radiological ap-
earance (including irregular aortic wall, rapid growth rate,
r saccular appearance of the aneurysm). Negative blood
ultures and absence of pyrexia were not used as exclusion
riteria when the patient had presented with signs of infec-
ion and had characteristic radiological findings but had
lready been commenced on antibiotics. Infected previous
ortic open or endografts were excluded from the series.
Demographic details, site of aortic infection, clinical
resentation, leukocytosis (white cell count 10.000/
L), fever (37.5 °C at presentation), results of blood and
ntraoperative cultures, complicating conditions, and peri-
perative and long-term survival data are presented.
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A total of 19 MAAs were identified in 17 patients, 12
men and 5 women, with a median age of 66.2 years (range,
49-82 years). Preoperatively, six patients were potentially
immunocompromised due to renal failure requiring hemo-
dialysis (n 3), multiple myeloma (n 1), discoid lupus in
remission (n  1), and diabetes mellitus (n  1). The
patient comorbidities are reported in Table I.
All 17 patients were symptomatic, presenting with a
range of symptoms, including abdominal and back pain,
weight loss, vomiting, anorexia, and hemoptysis. Fever was
present in 11, all had raised C-reactive protein, and the
white cell count was elevated in 11. Fourteen (82%) pa-
tients had received preoperative antibiotics. All patients had
typical radiological findings for MAAs, including 10 saccu-
lar aneurysms, five with radiological evidence of periaortic
inflammation, two with associated abscess, one with rapid
expansion, and two with irregular aneurysmal wall and
erosion into vertebral bodies.
Results are presented in Table II. Blood or aneurysmal
tissue cultures isolated Staphylococci (n  6), Streptococci
(n  4), one micrococcus (which was likely to be a contam-
inant), and one Prevotella (Fig 1). In six patients, no
organismwas identified. An identifiable source for infection
was present in seven of the patients. Two patients presented
with previous episodes of osteomyelitis (Fig 2), one of
whom had had a psoas abscess drained 2 months prior to
presentation, two patients had been previously hospitalized
due to chest sepsis, two had previous urinary tract sepsis,
and one had suffered an insect bite on the neck, compli-
cated with painful abscess formation requiring drainage
with positive blood culture for Prevotella. In six patients,
no organism was identified presumably because broad-
spectrum antibiotic treatment had already been com-
Table I. Patient characteristics
n %
Cardiovascular risk n %
Diabetes 1 6
Hypertension 11 65
Renal impairment 3 18
Stroke 3 18
Ischemic heart disease 3 18
Hyperlipidemia 7 41
Smoker (ex or current) 14 82
Symptoms
Fever 11 65
Abdominal/back pain 13 76
Gastrointestinal tract disturbance 2 12
Weight loss 5 29
Hemoptysis 1 6
Anorexia 5 29
Source
Osteomyelitis 2 12
Urosepsis 2 12
Chest sepsis 2 12
Abscess (drained) 1 6menced at the time of definitive diagnosis. tThere were five infrarenal, two juxtarenal, three Craw-
ord type III TAAAs, four type IV TAAAs, and five de-
cending thoracic aneurysms (one with an associated aor-
obronchial fistula). Two patients had concomitant MAAs;
ne with a descending mycotic thoracic aneurysm with a
egment of normal aorta and then a ruptured type IV
AAA (Fig 3, A), the other with a ruptured descending
horacic MAAwith a normal visceral aorta and an infrarenal
ycotic aneurysm. A type II TAAA was identified on a
ostoperative computed tomography (CT) in a patient that
nderwent emergency open repair of a ruptured infrarenal
neurysm who was too unstable to undergo any imaging
efore surgery. Ten patients presented with contained rup-
ure on admission (58.8%): one type III, three type IV, four
escending thoracic (Fig 4), one infrarenal, and one jux-
arenal. Two patients had associated bilateral common iliac
neurysms, and a female patient had a mycotic left subcla-
ian artery aneurysm that required treatment at a later stage
Fig 5).
All of the descending thoracic aneurysms were ex-
luded by endovascular stent graft repair (TEVAR; n 5).
f the three patients presenting with type III MAAs, two
nderwent single-stage visceral hybrid endovascular proce-
ure with aortic stenting and retrograde visceral revascular-
zation, and the third was treated with conventional open
epair via a thoracolaparotomy. All four patients with type
VMAAs underwent open repair, two via a rooftop incision
nd two via a thoracolaparotomy. Two of the infrarenal
neurysms were treated with bifurcated endovascular stents
EVAR) and three with open repair. These last three pa-
ients and the two with juxtarenal MAAs underwent exten-
ive tissue debridement and in situ reconstruction, one with
emoral vein and the rest with Dacron prosthesis. Cerebro-
pinal fluid drainage was used preoperatively in seven of the
1 patients where the thoracic aorta was involved in the
neurysm exclusion. The median hospital stay was 28.9
ays (range, 3-90 days).
Early outcome (<30 days postprocedure): The 30-
ay mortality was 17.6%; three patients out of 17. Two of
he three presented with aortic rupture (thoracic and type
II). One patient died on the table due to cardiac arrest, a
econd due to multiorgan failure on day 23 in the intensive
reatment unit, and the third death was due to bowel
schemia on day 16. In-hospital complications included
cute coronary syndrome (n 3), atrial fibrillation (n 1),
cute renal failure needing hemofiltration (n  5), respira-
ory failure (n  6, with four of them requiring tracheos-
omy), and cerebral ischemia (n  2), comprising one
ransient ischemic attack and one stroke. No patients de-
eloped spinal cord ischemia. The only early endovascular
omplication was a type Ib endoleak treated with a further
horacic stent extension.
Five patients needed additional open surgical proce-
ures during the same hospital stay. A patient with an open
ype IV repair developed a proximal anastomotic leak,
hich mandated a redo type III repair with revasculariza-
ion of the right kidney from the hepatic artery 15 days after
he original procedure. An urgent laparotomy was per-
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August 2011336 Vallejo et alformed for a patient who developed peritonism following a
TEVAR procedure. Extensive small and large bowel necro-
sis was found, and no surgical intervention was possible.
Another patient required a femoropopliteal bypass 9 days
after an open juxtarenal repair due to an ischemic foot. A
patient with a pigtail catheter inserted to drain a hemotho-
rax had to undergo an exploratory thoracotomy due to
bleeding when the pigtail has retrieved. One patient had to
be returned to theater with bleeding from a surgical trache-
ostomy.
Late outcome (>30 days postprocedure). The me-
dian clinical follow-up was 30.5 months (range, 1-102
months). There were three late deaths. One patient died as
a result of multiple myeloma 10 months postoperatively,
the other due to bowel ischemia 5 years and 1 month later.
The third patient who died presented with abdominal pain
and coffee ground vomiting 11 months post-TEVAR. No
cause of death was determined.
There was only one late type II endoleak in a patient
who had undergone TEVAR, picked up following a surveil-
lance CT scan at 6 months. This spontaneously resolved by
the 10th month.
Two patients required further surgery on a second
hospital admission. A visceral hybrid was performed 9
months after an open infrarenal repair due to a type II
thoracoabdominal aneurysm. This patient did not undergo
a CT preoperatively due to the emergent nature of the
ruptured aneurysm. A female patient with a previous open
type IV repair for a ruptured mycotic type IV TAAA and a
TEVAR for a saccular descending thoracic aneurysm (see
Fig 3, B) also had a left subclavian artery origin mycotic
aneurysm. A right-to-left carotid-carotid crossover graft
and a left carotid-subclavian bypass were performed, fol-
lowed by coverage of the origin of the left subclavian and
left carotid arteries with a thoracic endograft 16 months
after the original emergent repair.
Fifteen patients received postprocedural antibiotics,
which were organism-specific if there was a positive tissue
or blood culture, or an empiric regimen in those with no
identified organism. The duration of the treatment was
variable ranging from 6 weeks to lifelong based on micro-
biological advice.
DISCUSSION
Mycotic aneurysms of the abdominal, thoracic, and
particularly the thoracoabdominal aorta are rare entities
that present significant challenges to the vascular surgeon.
The gold standard treatment of resection of the infected
aorta with aggressive debridement of periaortic tissues fol-
lowed by reconstruction of the aortic flow in-line or extra-
anatomically is associated with a high morbidity and mor-
tality rate even in the most experienced hands.1,5,6 We have
previously reported our experience of treating 15 mycotic
aortic aneurysms between 1991 and 2001, and reported an
early mortality of 26.7% and a total mortality of 40% with a
38-month follow-up. In this series of cases presenting from
2002 to 2010, the early mortality rate is 17.6%, and total
mortality is 35.3%, with a 30.5-month follow-up period. uhe two series are incomparable given the heterogeneity of
ases; there were no thoracic aneurysms reported in the first
eries, but the time frame encompassed has been marked by
he endovascular revolution in vascular surgery. In the first
eries, every case was treated by open surgery, and the main
ontroversy revolved around in situ versus extra-anatomical
ypass. In the latest series, we have utilized endovascular
tent grafts in nine of 19 (47.4%) aneurysms, and used them
n the infrarenal, visceral, and thoracic segments of the
orta. All thoracic aneurysms were treated with TEVAR.
he thoracoabdominal segment was treated by a combina-
ion of open surgery (four type IV, one type III) and a
ybrid endovascular approach (two type III); all juxtarenal
neurysms were treated by open repair, and three infrarenal
epairs were open, two by EVAR.
The use of endovascular stents to treat mycotic aneu-
ysms has the obvious potential to reduce mortality and
orbidity by avoiding open repair, full anticoagulation,
ignificant blood loss, aortic cross-clamping, single-lung
entilation, prolonged distal ischemia, and possible cardio-
ulmonary bypass.8 The first mycotic infrarenal aneurysms
reated with EVAR were reported by Semba and cowork-
rs9 with very good results in three cases. Since then, there
ave been many series of cases10-19 and two systematic
eviews20-21 described in the literature. The literature
ainly concentrates on abdominal and thoracic mycotic
neurysms, where a wholly endovascular approach can be
dopted. The survival analyses published show promising
arly andmidterm results. In our series, patients considered
t enough to survive surgery for infra- and juxtarenal
ycotic aneurysms underwent open repair. The two cases
elected for EVARwere chosen predicated on the perceived
nability of the patients to survive open surgery; an 82-year-
ld with significant comorbidities and a 67-year-old with a
uptured thoracic mycotic aneurysm and a synchronous
onruptured infrarenal mycotic aneurysm. All five thoracic
neurysms were treated with TEVAR: four had ruptured
ith contained leak, and one was associated with a ruptured
ycotic type IV TAAA that required immediate open
epair.
Anatomical location of the aneurysm is a key factor in
ecision making. Descending thoracic aneurysms are ame-
able to a wholly endovascular approach, and the reduction
n perioperative mortality and neurological morbidity com-
ared with open surgery has been well described for ath-
rosclerotic thoracic aneurysms.22 These results are also
bserved for mycotic aneurysms, with an open surgical
ortality of 28%,3 compared with 15% for TEVAR.13 Even
hough long-term results with TEVAR remain to be seen,
hemidterm results reported are encouraging. In our series,
ven though four of five mycotic thoracic aneurysms were
uptured, there was only one perioperative death. We
ould advocate TEVAR for all ruptured mycotic thoracic
neurysms, and most of the intact ones. We would only
onsider open repair for intact mycotic thoracic aneurysms
t the younger end of the age spectrum.
Thoracoabdominal mycotic aneurysms present a partic-
lar problem due to the visceral side branches. Open sur-
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recently.1,23 Cina et al reported 73 cases in a systematic
review of the literature between 1966 and 1999, and all
reported cases were treated by in situ or extra-anatomical
replacement.24 The advent of hybrid endovascular tech-
niques25 has now opened up new therapeutic possibilities
in the treatment of thoracoabdominal mycotic aneurysms,
although there have been only been three cases reported in
the literature.10,13,15 The advantages offered by an endo-
vascular approach are particularly pertinent in this group of
patients who are often profoundly unwell due to a combi-
Fig 1. Microbi
Table II. Results
Gender/Age Fever (Y/N) White cell count C-reactive pr
M/67 Y 33.3 330
M/62 N 17.7 315
M/68 Y 10.3 67
M/67 N 12.1 300
F/59 Y 9.0 56
F/80 Y 21.5 135
M/64 Y 9.4 —
F/57 N 5.6 193
F/63 Y 17.6 152
F/72 N 3.2 200
M/68 N 14.1 93
M/59 N 7.0 22
M/72 Y 10.2 270
M/71 Y 9.7 53
M/82 Y 7.7 64
M/49 Y 20.4 178
M/65 Y 12.8 —
AF, Atrial fibrillation;ARF, acute renal failure requiring hemofiltration; EVA
JRAAA, juxtarenal abdominal aortic aneurysm; TA, thoracic aneurysm; TEnation of sepsis and rupture. In our cohort of patients, open gurgery was performed for all four cases of Crawford type
V TAAA. The procedure is performed via a thoracolapa-
otomy or an abdominal roof top approach, dividing the
eft crus of the diaphragm and exposing the aorta with a
edial visceral rotation. The anastomosis is performed in
n oblique fashion, with inclusion of all the visceral vessels,
lthough the left renal arterymay need to be reimplanted.26
he mortality of this technique in our center for atheroscle-
otic aneurysms is low, with a 30-day mortality rate of 4.9%
or elective cases and 17.4% for urgent and ruptured aneu-
ysm repairs in 105 consecutive procedures between Au-
culture results.
Organism Aneurysm Rupture
Micrococcus TA Y
None TA Y
Staph aureus TA Y
None TA  IRAAA Y
Prevotella, S pneumoniae TA  type IV Y
None Type III N
None Type III Y
Strep pneumoniae, Klebsiella Type III N
Group A Strep Type IV Y
Strep bovis Type IV Y
Staph aureus Type IV N
Coag ve Staph JRAAA N
Coag ve Staph JRAAA Y
None IRAAA N
Staph Warneii IRAAA N
None IRAAA N
Coag Neg Staph IRAAA Y
dovascular aneurysm repair; IRAAA, infrarenal abdominal aortic aneurysm;
thoracic endovascular aneurysm repair.otein
R, enust 2001 and January 2009. In this series, the periopera-
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cases were ruptures. We feel open surgery for this group is
the optimum treatment modality.
The more extensive type III cases were treated unsuc-
cessfully with open surgery in one case and successfully with
a hybrid endovascular approach involving retrograde vis-
ceral artery revascularization and aortic stenting in two
patients felt to be too unwell to survive an open procedure.
Both of these patients survived with no further intervention
required. The emergency open procedure was performed
 
 
Fig 2. Computed tomography scan demonstrating mycotic
TAAA with vertebral body erosion (arrow).
Table II. Continued
Procedure Complications
TEVAR Septic shock, AF, bowel infarction, lapa
TEVAR Chest sepsis, AF, type II endoleak
TEVAR None
TEVAR, EVAR None
TEVAR, open type IV Tracheostomy, thoracotomy for bleedin
transient ischemic attack, ARF
Visceral hybrid None
Open type III Intraoperative cardiac arrest
Visceral hybrid ARF, tracheostomy, bleeding from
tracheostomy
Open type IV ARF, respiratory arrest, leaking proxim
anastamosis requiring reoperation
Open type IV Tracheostomy, cardiac arrest
Open type IV ARF, tracheostomy
Open ARF
Open ARF, limb ischemia
Open ARF
EVAR None
Open None
Open Chest infection, AFfor rupture, while the cases treated by hybrid procedures uad intact aneurysms and time to bring sepsis under control
nd for careful procedural planning. Following blood cul-
ures, the patients were commenced on intravenous antibi-
tics in an attempt to prevent intraoperative hematogenous
eeding of the surgical retrograde iliac to visceral grafts and
o optimize the patient’s medical status by treating associ-
ted systemic sepsis. Both procedures were undertaken in a
ingle episode rather than as staged procedures in line with
ur usual practice. A hybrid surgical approach to ruptured
AAAs is fraught with potential hazards. Dissection to
xpose adequate lengths of the visceral arteries is problem-
tic in the presence of retroperitoneal hematoma, and
onversion to free rupture is a possibility with no site for
roximal clamping exposed.
The principle problem with a hybrid endovascular
pproach is the theoretic risk of subsequent prosthetic
nfection in the retrograde visceral grafts and the aortic
ndograft. The problem of recurrent sepsis from an
nfected endograft has led to the suggestion that endo-
ascular repair can be utilized as a bridging procedure for
igh-risk patients, with subsequent definitive open sur-
ery. While explanting a stent graft in the infrarenal aorta
s feasible, open removal and replacement of thoracic and
horacoabdominal endografts represent an enormous
urgical insult, and a hybrid endovascular repair for
ycotic TAAAs needs to be viewed as the definitive
reatment option.
For juxta- and infrarenal aneurysms, our preference
as been open repair because it is a durable option with
cceptable mortality rates and the opportunity to directly
ebride infected periaortic tissues. In our previous re-
orted study, the 30-day mortality rate was 16%7 in this
roup, while there were no deaths in the five patients
30-day mortality Current status Follow-up (months)
y Y Dead 0
N Dead 9
N Alive 64
N Alive 1
N Alive 17
N Alive 40
Y Dead 0
N Alive 9
N Alive 87
N Dead 10
Y Dead 0
N Alive 102
N Alive 24
N Alive 32
N Alive 27
N Alive 68
N Dead 28rotom
g,
alndergoing open surgery in the current series. Nonethe-
F
B
complete shrinkage of aneurysmal sac.
F
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 2 Vallejo et al 339less, an endovascular approach was still utilized in two
patients because of patient-associated factors. Both were
compromised, one by a synchronous thoracic aneurys-
mal rupture, and the other by age and comorbidity. Both
were treated by bifurcated EVAR devices, and both
survived. We feel EVAR offers an excellent option for
that group of patients in whom it is felt open repair
carries significant procedural risks.
In conclusion, treatment of MAAs has altered over the
Fig 3. A, Computed tomography scan showing mycotic thoracic
aneurysm and ruptured mycotic type IV aneurysm (arrowed).
B, Endovascular repair of the thoracic component following
open repair of the ruptured type IV aneurysm.last decade with the advent of endovascular repair. The cig 4. A, Ruptured mycotic descending thoracic aneurysm.
, Computed tomography 9 months post-TEVAR demonstratingig 5. Concomitant left subclavian and descending thoracic my-
otic aneurysms.
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August 2011340 Vallejo et alprecise role of endovascular stenting of mycotic aneurysms
remains to be elucidated, but each patient needs to be
treated on a case-by-case basis predicated on location,
rupture, and comorbidity. We continue to use open repair
as a gold standard approach wherever possible, but endo-
vascular treatment has increased the therapeutic options for
a difficult and diverse group of patients.
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